11-50 employees

founded in

September 2021

resistanceBio has built the first cancer treatment resistance system to predict how multiple cancer types will respond to approved or novel treatments. The ResCu platform aims only to advance therapies that have the potential to be superior to the standard of care and significantly extend patients’ lives. ResCu addresses the root cause of treatment failure, which is treatment resistance.

Is this your company?

If you're responsible for hiring at this company, make sure your company and job information are always up to date to attract top talent from the NFX Guild network.

Something looks off?
Open jobs at resistanceBio
This company does not have jobs relevant to this job board at this time.
To view all their jobs, visit their website.